Regeneron
Pays vs peer median
×0.85
-15% premium
Sample
25
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×0.83 | 22 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 3 | ×0.75 | 6 |
| preclinical | ×0.74 | 6 |
| approved | ×1.50 | 5 |
| phase 1 | ×0.73 | 4 |
| phase 2 | ×0.70 | 3 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Multiple targets (collaboration expansion) | CytomX Therapeutics | cancer | unknown | — | $2.0B |
| 2026 | Probody-based immunotherapies (collaboration expansion) | CytomX | immuno-oncology | unknown | $37M | $2.0B |
| 2026 | Probody technology (expansion) | CytomX Therapeutics | oncology and/or immunology | unknown | $37M | $2.0B |
| 2026 | ADC technology platform | Parabilis | — | unknown | — | $2.3B |
| 2026 | Probody conditionally activated biologics platform (includes REGN7075 and additional preclinical oncology targets) | CytomX Therapeutics | oncology | preclinical | $37M | $2.0B |
| 2026 | Radiopharma program | Telix | — | unknown | — | $2.1B |
| 2026 | — | Telix Pharmaceuticals Limited | solid tumors including lung cancer | discovery | $40M | $2.1B |
| 2025 | ICOS-101 | Zai Lab | Bladder | preclinical | $81M | $900M |
| 2025 | Anti-CEA-tinib | Monte Rosa Therapeutics | HCC | discovery | $5M | $93M |
| 2025 | Anti-LAG-3-mab | TCR2 Therapeutics | Bladder | phase_3 | $483M | $3.7B |
| 2025 | Anti-CD38-mab | Denali Therapeutics | AML | discovery | $36M | $678M |
| 2025 | B7-H4-201 | Hengrui Medicine | AML | preclinical | $19M | $272M |
| 2025 | Anti-ICOS-301 | Alphamab Oncology | MDS | phase_1 | $68M | $870M |
| 2025 | TIGIT-301 | CytomX Therapeutics | AML | discovery | $30M | $410M |
| 2025 | PI3K-001 | Junshi Biosciences | Breast (HER2+) | phase_3 | $980M | $8.5B |
How this is computed
For each Regeneron deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 25 disclosed deal premiums vs. peer medians. Raw premium 0.850, clamped to [0.7, 1.5].